Prognostic role of p53 accumulation in patients with metastatic medulloblastoma (M +)

Introduction: Metastatic disease (M+) at diagnosis is the most important negative prognostic clinical marker in medulloblastoma (MB) patients and despite the use of craniospinal irradiation and chemotherapy is one of the leading causes of treatment failure. Few parameters have been evaluated to obtain a prognostic profile for these high-risk patients. Methods: Material of 169 patients with metastatic MB registered to the HIT2000 trial of the German Society of Pediatric Oncology and Haematology has been investigated to determine the role of p53 protein expression in predicting survival. Results: 159 patients with…